A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer

Cancer

Volumn 118, Issue 23, 2012, Pages 5733-5740

  Beeram, Muralidhar ^a   Krop, Ian E ^b   Burris, Howard A ^c   Girish, Sandhya R ^d   Yu, Wei ^d   Lu, Michael W ^d   Holden, Scott N ^d   Modi, Shanu ^e  

^a CTRC Institute for Drug Development   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d GENENTECH INC   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

antibody drug conjugate; breast cancer; HER2 positive; T DM1; trastuzumab emtansine

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR 2; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLEEDING; BREAST CANCER; CALCIUM BLOOD LEVEL; CELLULITIS; CHILL; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSGEUSIA; DYSPNEA; EPISTAXIS; EYE DISEASE; FATIGUE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNOGENICITY; INFLUENZA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LUNG DISEASE; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; OSTEOMYELITIS; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SODIUM BLOOD LEVEL; STEADY STATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOTOXINS; MAXIMUM TOLERATED DOSE; MAYTANSINE; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 84869508508     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27622     Document Type: Article

References (12)

1. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68: 9280-9290.
2. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX,. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011; 128: 347-356.
3. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010; 28: 2698-2704.
4. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011; 29: 398-405.
5. Hurvitz SA, Dirix L, Kocsis J, et al. Trastuzumab emtansine (T-DM1) versus trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase 2 study (TDM4450g/BO21976) [abstract]. Eur J Cancer. 2011; 47 (suppl 1): s330. Abstract 5001.
6. Helft PR, Schilsky RL, Hoke FJ, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004; 10: 4363-4368. (Pubitemid 38878875)
7. Milowsky MR, Galsky M, George DJ, et al. Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC) [abstract]. J Clin Oncol. 2006; 24 (18s): 217s. Abstract 4500.
8. Therasse P, Arbuck SG, Eisenhauser EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000; 92: 205-216. (Pubitemid 30099779)
9. Lu D, Gupta M, Wang B, et al. An integrated population pharmacokinetic model for a first-in-class HER2 targeted antibody-drug conjugate trastuzumab emtansine (T-DM1): simultaneous modeling of T-DM1 and total trastuzumab pharmacokinetics in heavily pretreated HER2+ metastatic breast cancer patients [abstract]. Clin Pharmacol Ther. 2011; 89 (suppl 1): S54. Abstract PII-51.
10. Bender BC, Schaedeli-Stark F, Joshi A, et al. A semi-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC [abstract]. J Clin Oncol. 2011; 29 (15s):71s. Abstract 605.
11. Mahapatra K, Darbonne W, Bumbaca D, et al. T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner [abstract]. Mol Cancer Ther. 2011; 10 (11 suppl). Abstract A135.
12. Krop IE, Modi S, Elias A, LoRusso P, Choi YJ, Lu M,. A dose-escalation study of trastuzumab-DM1 (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive, locally advanced or metastatic breast cancer (MBC) previously treated with a trastuzumab-containing regimen [abstract]. Cancer Res. 2010; 70 (suppl 2): 295s. Abstract P3-14-10.